ALNYLAM PHARMACEUTICALS, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $18.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-12
- ALNYLAM PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $18.30M.
- ALNYLAM PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$571.93M.
- ALNYLAM PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$450.31M.
- ALNYLAM PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$1.15B.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $18.30M 10-K · filed 2026-02-12 |
| 2024-12-31 | -$571.93M 10-K · filed 2026-02-12 |
| 2023-12-31 | -$450.31M 10-K · filed 2026-02-12 |
| 2022-12-31 | -$1.15B 10-K · filed 2025-02-13 |
| 2021-12-31 | -$794.73M 10-K · filed 2024-02-15 |
| 2020-12-31 | -$682.86M 10-K · filed 2023-02-23 |
| 2019-12-31 | -$597.60M 10-K · filed 2022-02-10 |
| 2018-12-31 | -$573.25M 10-K · filed 2021-02-11 |
| 2017-12-31 | -$378.29M 10-K · filed 2020-02-13 |
| 2016-12-31 | -$350.70M 10-K · filed 2019-02-14 |
| 2015-12-31 | -$245.68M 10-K · filed 2018-02-15 |
| 2014-12-31 | -$372.14M 10-K · filed 2017-02-15 |
| 2013-12-31 | -$81.11M 10-K · filed 2016-02-12 |
| 2012-12-31 | -$116.40M 10-K · filed 2015-02-13 |
| 2011-12-31 | -$57.48M 10-K · filed 2014-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |